Dishman Carbogen Amcis Ltd. · NSE:DCAL
Dishman Carbogen Amcis — Q1 FY21 Earnings Presentation
27 slides from Dishman Carbogen Amcis's earnings presentation, Sep 8, 2020
Slide 1: Cover letter to stock exchanges
dish man sth September, 2020 To, To, Department of Corporate Services The Manager, BSE Ltd. Listing Department, Phiroze Jeejeebhoy Towers, National Stock Exchange of India Ltd. Dalal Street, "Exchange Plaza", C-1, Block G, Mumbai - 400 001. Bandra-Kurla Complex, Sandra (E), Mumbai - 400 051. Ref.: S
Slide 2: Quarter ended June 30th, 2020
Quarter ended June 30th, 2020 September 2020
Slide 3: Safe Harbor Statement
SAFE HARBOR STATEMENT This presentation and the following discussion may contain “forward looking statements” by Dishman Carbogen Amcis Limited (‘Dishman’ or the ‘Company’) that are not historical in nature. These forward- looking statements, which may include statements relating to future results o
Slide 4: Dishman in a Nutshell
Dishman in a Nutshell 4 decades 2,200+ Team Strength 25 28 Committed Members Embracing of Long-Standing Track Record in our Culture of Innovation & Sustainability CRAMS Dedicated Team/Scientist Working Multi-Purpose MANUFACTURING RESEARCH & DEVELOPMENT APIS in R&D - 950+ FACILITIES Globally and HIPO
Slide 5: Past Performance at a Glance
Past Performance at a Glance Revenue from Operations (₹ mn) EBITDA and EBITDA % Cash Profit (₹ mn) EBITDA EBITDA % 4,499 4,273 20,586 20,436 5,519 5,224 3,660 16,017 17,137 16,948 4,534 4,453 2,945 2,994 4,103 26.8% 26.5% 26.3% 25.6% 25.6% FY16 FY17 FY18 FY19 FY20 FY16 FY17 FY18 FY19 FY20 FY16 FY17
Slide 6: Agenda
AGENDA 01 Quarter Highlights 02 Company Overview 03 Industry Overview 5
Slide 7: Quarter Highlights
CARBOGEN @dishman (7 ses” QUARTER
Slide 8: Impact due to Covid-19
Impact due to Covid-19 Cautionary Statement The business operations remained shutdown temporarily during the quarter owing to the lockdown imposed due to Covid-19 pandemic. Moreover, the business was also impacted due to certain observations from the European Directorate for the Quality of Medicines
Slide 9: Q1 FY21 Result Highlights
Q1 FY21 RESULT HIGHLIGHTS REVENUE (₹ mn) EBITDA (₹ mn) & EBITDA MARGIN* 5,219 1,319 5,121 1,194 25.8% 4,744 22.9% 431 9.1% Q1FY20 Q4FY20 Q1FY21 Q1FY20 Q4FY20 Q1FY21 ADJUSTED PBT# (₹ mn) & PBT MARGIN CASH PAT@ (₹ mn) & CASH EPS 819 6.0 7.0 683 1,129 16.0% 964 13.1% 2.7 430 -2.4% -115 Q1FY20 Q4FY20 Q1
Slide 10: Consolidated P&L Statement
CONSOLIDATED P&L STATEMENT Particulars (₹ mn) Q1 FY21 Q1 FY20 YoY % Q4 FY20 QoQ % FY20 Revenue from Operations 4,751.3 5,012.9 -5.2% 5,028.3 -5.5% 19,732.6 Other Operating Income -7.2 206.1 - 92.9 - 703.4 Total Revenue 4,744.1 5,219.0 -9.1% 5,121.2 -7.4% 20,436.0 COGS 1,487.4 1,302.6 14.2% 1,113.1 3
Slide 11: Segment Wise Revenue Analysis
SEGMENT WISE REVENUE ANALYSIS Revenues – Segment wise Breakup (₹ mn) Q1 FY21 Q1 FY20 Q4 FY20 FY20 CRAMS CRAMS- India 147.8 767.3 916.7 3,323.5 CRAMS – Switzerland, France & China 3,089.8 2,631.7 2,783.2 10,815.3 CRAMS - UK 251.8 375.3 152.2 964.5 CRAMS Total 3,489.4 3,774.4 3,852.1 15,103.3 Marketab
Slide 12: Segment Wise Revenue Break-up
SEGMENT WISE REVENUE BREAK-UP Total Operating Revenue - Q1 FY21 CRAMS – 73.4% Marketable Molecules – 26.6% 7% 4% 42% 58% 89% CRAMS - India CRAMS - Switzerland & France Carbogen Amcis BV Others CRAMS - UK 11
Slide 13: Segment-wise Margin Analysis
SEGMENT-WISE MARGIN ANALYSIS EBITDA Margin* % Q1 FY21 Q1 FY20 Q4 FY20 FY20 CRAMS CRAMS- India NA 51.6% 53.4% 55.5% CRAMS – Switzerland, France & China 16.2% 18.2% 20.8% 20.4% CRAMS - UK 15.3% 11.9% 14.4% 16.4% Marketable Molecules Carbogen Amcis BV 32.3% 31.0% 26.9% 32.0% Others 12.9% 9.8% 10.2% 10.
Slide 14: Q1 FY21 Result Highlights
Q1 FY21 RESULT HIGHLIGHTS Total Revenues at Rs 4,744.1 mn in Q1 FY 2021 down by 9.1% YoY CRAMS revenue decreased 7.6% YoY primarily due to : CRAMS India revenue decreased by 80.7% YoY, due to impact of COVID-19 pandemic and risk analysis measures undertaken due to EDQM audit observations CRAMS Carbo
Slide 15: Company Overview
CARBOGEN @dishman (7 ses” COMPANY
Slide 16: About Us
ABOUT US Established in 1983, Dishman Carbogen Amcis Limited is a fully integrated CRAMS (Contract Research & Manufacturing) company with strong capabilities right from process research & development to late stage clinical and commercial manufacturing and supply of API to innovator pharmaceutical co
Slide 17: Key Strengths
KEY STRENGTHS Preferred global outsourcing Upfront investment of more partner with capabilities across the than ₹10,000 mn in large entire CRAMS value chain scale multi-purpose manufacturing capacities Strong chemistry skills The HIPO facility at Bavla, India is the largest HIPO facility in Asia. Di
Slide 18: Manufacturing Facilities
ROBUST R&D CAPABILITIES Facilities are approved by recognised health agencies: USFDA, MEB, SWISS MEDIC, ANSM, WHO, MFDS, PMDA Superior Chemistry Skills & Capabilities CARBOGEN AMCIS BV., CARBOGEN AMCIS Veenendaal, The Netherlands (Shanghai) Co. Ltd. 28 dedicated R&D labs with multiple shift R&D Chin
Slide 19: Preferred Global Outsourcing Partner
PREFERRED GLOBAL OUTSOURCING PARTNER CLOSE PROXIMITY LARGE SCALE INTEGRATED ACROSS THE STRONG CHEMISTRY TO CLIENTS WITH MANUFACTURING VALUE CHAIN CAPABILITIES GLOBAL PRESENCE CAPACITIES Integrated CRAMS Player present along the entire value chain from building blocks to commercialization and product
Slide 20: Integrated CRAMS Player
INTEGRATED CRAMS PLAYER CARBOGEN AMCIS (CA) STRONG RESEARCH CAPABILITIES Focus is on supporting the development process from bench to market Process research and development to the supply of APIs for preclinical studies, clinical trials and commercial use DISHMAN INDIA STRONG MANUFACTURING CAPAB
Slide 21: Cutting Edge HIPO Capabilities
CUTTING EDGE HIPO CAPABILITIES The HIPO facility at Bavla, India, is one of the kind facility in the world and the largest facility in Asia. The facility has a sound mix of Kilo lab and full- scale manufacturing units to cater to both small volume and large volume orders. State of the art containmen
Slide 22: Therapeutic Area Split
THERAPEUTIC AREA SPLIT DEVELOPMENT COMMERCIAL 22% 21% 28% 32% New Dev Commercials 4% 11% Projects FY20 FY20 4% 18% 17% 11% 14% 6% 6% 4% 4% Cancer ADC-Warhead/ADC Eyes Antibiotic Blood/Immunology Hormone/Metabolism Pain/Nerves Diabetes Various APIs Non-APIs/Intermediates 21
Slide 23: Industry Overview
CARBOGEN @dishman (7 ses” INDUSTRY
Slide 24: Top 10 Therapy Areas (US$ bn) - 2019
2019 Global Sales by Therapy Areas Specialty areas dominate sales and growth driven by developed markets 0 20 40 60 80 100 120 140 160 Oncologics 44% 22% 8% 11% 15% $146 bn $97 bn Top 10 Therapy Areas (US$ bn) - 2019 11% Antidiabetics 66% 8% 5% 10% 11% $87 bn 2% Autoimmune Diseases 69% 14% 4% $47 bn
Slide 25: Specialty: Market Share & Growth
SPECIALTY: MARKET SHARE & GROWTH Developed countries account for >80% of specialty market Specialty: Region Market Share 2019 Region Contribution to Global Growth 81% of all specialty sales from 7 countries 2014-19 2014-19 Absolute growth contribution in LCUS$ Market Specialty 12% 13% 13% US 6% 5% 2
Slide 26: Pharmerging Markets - Oncology Leads Growth
PHARMERGING MARKETS - ONCOLOGY LEADS GROWTH Pharmerging Top 10 therapy areas, value and volume growth 32% 17% Value PPG (%) 14%13% 13%12% 11% 10% 10% 9% 9% 8% 8% 8% 9% 7% 7% 5% 5% 2% 3% 4% 12% 11% 10% 9% 8% Volume PPG (%) 5% 6% 6% 3% 3% 3% 4% 4% 4% 4% 4% 4% 0% 0% 1% -2% -1% Pharmerging Antibacterial
Slide 27: Thank you!
Dishman Dishman Corporate House CARBOGEN AMCIS AG Iscon-Bopal Road, Ambli Hauptstrasse 171 Ahmedabad – 380058 CH-4416 Bubendorf Gujarat, India Switzerland www.dishmangroup.com www.carbogen-amcis.com Thank you! FOR FURTHER QUERIES Mr. Binay Sarda Mr. Harshil Dalal Christensen IR Group CFO P: +91 22 4
Dishman Carbogen Amcis — Q1 FY21 Earnings Presentation on 6ix